Three studies of bioTheranostics molecular breast cancer diagnostics presented at sym

[News]

bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in individual patients.

More... (http://www.news-medical.net/?id=44198)